Table 1.
Demographics and Clinical Characteristics of 17 Patients With HIV-KS
| Demographic or Clinical Characteristic | No. of Patients | % |
|---|---|---|
| Age, years | ||
| Median | 44 | |
| Range | 23-65 | |
| Sex | ||
| Male | 16 | 94 |
| Female | 1 | 6 |
| Race | ||
| Black | 8 | 47 |
| White | 6 | 35 |
| Hispanic | 3 | 18 |
| KS prognostic factors* | ||
| T1 | 13 | 76 |
| I1 | 5 | 29 |
| S1 | 4 | 24 |
| Revised TS staging† | ||
| Good (T0S0, T1S0, or T0S1) | 2 | 12 |
| Poor (T1S1) | 15 | 88 |
| CD4 count, cells/μL | ||
| Median | 294 | |
| Range | 7-654 | |
| < 200 | 7 | 41 |
| Time on HAART, months | ||
| Median | 12 | |
| Range | 1-90 | |
| HIV viral load, copies/mL | ||
| Median | < 50 | |
| Range | < 50-180,000 | |
| < 50 | 14 | 82 |
| Detectable circulating KSHV‡ | 5 | 31 |
| Prior therapy for KS | ||
| Chemotherapy | 13 | 76 |
| Liposomal doxorubicin | 12 | 71 |
| Paclitaxel | 5 | 29 |
| Other§ | 2 | 12 |
| Immunotherapy | 11 | 65 |
| Radiation | 5 | 29 |
| Time since last chemotherapy | ||
| Median | 3 months | |
| Range | 3 weeks-8 years | |
Abbreviations: HAART, highly active antiretroviral therapy; KS, Kaposi's sarcoma; KSHV, Kaposi's sarcoma–associated herpes virus; TS, staging based on tumor and systemic illness.
Risk factors based on AIDS Clinical Trial Group staging criteria for extent of tumor (T), immune status (I), and systemic illness (S), as follows: T1, edema or ulceration, extensive oral mucosa KS, or visceral KS; I1, CD4 < 150 cells/μL; and S1, history of opportunistic infections or thrush, and/or “B” symptoms present, and/or Karnofsky score < 70, and/or other HIV-related disease.
Revised AIDS KS prognostic criteria exclude CD4 as risk factor.
Baseline peripheral-blood mononuclear cell–associated KSHV viral load38 was assessed for the 16 evaluable patients. The five patients with detectable KSHV had a median of 190 copies/106 cells (range, 17 to 3,200 copies/106 cells).
Other chemotherapies included etoposide, vincristine, vinblastine, vinorelbine, and bleomycin.